Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 20/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2007203 | 0.89 | FBP1 (1.00) | FBP1 | |
| SCHEMBL2008570 | 0.89 | FBP1 (1.00) | FBP1 | |
| SCHEMBL2010428 | 0.89 | FBP1 (1.00) | FBP1 | |
| SCHEMBL2010546 | 0.89 | FBP1 (1.00) | FBP1 | |
| SCHEMBL2012536 | 0.83 | FBP1 (0.88) | FBP1 | |
| SCHEMBL2009151 | 0.83 | FBP1 (0.88) | FBP1 | |
| SCHEMBL23447672 | 0.80 | HTT (0.61) | FBP1 | |
| SCHEMBL23447453 | 0.80 | CA1 (0.71) | — | |
| SCHEMBL28506679 | 0.77 | FBP1 (0.77) | FBP1 | |
| SCHEMBL23447452 | 0.77 | FBP1 (0.63) | FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964633-B2 | such as N,N'-[hexane-1,6-diylbis(iminocarbonyl)]bis(3-chlorobenzenesulfonamide), used as Fructose-1,6-bisphosphatase inhibitors; metabolic disorders such as diabetes | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | claimed |
| EP-2081889-B1 | SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | claimed |
| EP-2081889-A1 | SULFONAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-29 | — | — | EP | claimed |
| US-20080085928-A1 | Sulfonamide derivatives | HOFFMANN-LA ROCHE INC. | 2008-04-10 | — | — | US | claimed |
| WO-2008037628-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | claimed |
| US-7964633-B2 | such as N,N'-[hexane-1,6-diylbis(iminocarbonyl)]bis(3-chlorobenzenesulfonamide), used as Fructose-1,6-bisphosphatase inhibitors; metabolic disorders such as diabetes | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2081889-B1 | SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-20080085928-A1 | Sulfonamide derivatives | HOFFMANN-LA ROCHE INC. | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085928-A1 | Sulfonamide derivatives | SULT2A1, SULT1A1, SULT1E1 | FBP1 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.